Progress in pediatric kidney transplantation

Therapeutic Drug Monitoring

Volumn 32, Issue 3, 2010, Pages 250-252

  Filler, Guido ^a   Huang, Shih Han S ^a  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

Author keywords

Cardiovascular risk factors; Chronic kidney disease; Corticosteroids; Immunosuppression; Long term outcomes; Pediatric renal transplantation; Tacrolimus

Indexed keywords

CORTICOSTEROID; CYCLOSPORIN; DACLIZUMAB; GROWTH HORMONE; IMMUNOSUPPRESSIVE AGENT; MONOCLONAL ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN; TACROLIMUS;

BLOOD VESSEL CALCIFICATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; CONFERENCE PAPER; DIABETES MELLITUS; DIALYSIS; DRUG EFFECT; DRUG SAFETY; GRAFT SURVIVAL; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY ALLOGRAFT; KIDNEY FAILURE; KIDNEY GRAFT REJECTION; KIDNEY ISCHEMIA; KIDNEY TRANSPLANTATION; MORBIDITY; MORTALITY; OBESITY; PEDIATRIC SURGERY; PRIORITY JOURNAL; REPERFUSION INJURY; SURVIVAL TIME; UNSPECIFIED SIDE EFFECT;

CHILD; GRAFT REJECTION; HUMANS; HYPERTENSION; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; KIDNEY FAILURE, CHRONIC; KIDNEY TRANSPLANTATION; MYCOPHENOLIC ACID; REPERFUSION INJURY;

EID: 77952952138     PISSN: 01634356     EISSN: 15363694     Source Type: Journal    
DOI: 10.1097/FTD.0b013e3181dda53d     Document Type: Conference Paper

References (24)

1. Sciarretta S, Valenti V, Tocci G, et al. Association of renal damage with cardiovascular diseases is independent of individual cardiovascular risk profile in hypertension: data from the Italy-Developing Education and awareness on MicroAlbuminuria in patients with hypertensive Disease study. J Hypertens. 2010;28:251-258.
2. Parekh RS, Carroll CE, Wolfe RA, et al. Cardiovascular mortality in children and young adults with end-stage kidney disease. J Pediatr. 2002; 141:191-197.
3. Levey AS, Beto JA, Coronado BE, et al. Controlling the epidemic of cardiovascular disease in chronic renal disease: what do we know? What do we need to learn? Where do we go from here? Am J Kidney Dis. 1998; 32:853-905.
4. Hanevold CD, Ho PL, Talley L, et al. Obesity and renal transplant outcome: a report of the North American Pediatric Renal Transplant Cooperative Study. Pediatrics. 2005;115:352-356.
5. Querfeld U. The clinical significance of vascular calcification in young patients with end-stage renal disease. Pediatr Nephrol. 2004;19:478-484.
6. Silverstein D. Risk factors for cardiovascular disease in pediatric renal transplant recipients. Pediatr Transplant. 2004;8:386-393.
7. Ojo AO, Held PJ, Port FK, et al. Chronic renal failure after transplantation of a nonrenal organ. N Engl J Med. 2003;349:931-940.
8. Karthikeyan V, Karpinski J, Nair RC, et al. The burden of chronic kidney disease in renal transplant recipients. Am J Transplant. 2004;4:262-269.
9. Feber J, Wong H, Geier P, et al. Complications of chronic kidney disease in children post-renal transplantation\a single center experience. Pediatr Transplant. 2008;12:80-84.
10. Akbari A, Hussain N, Karpinski J, et al. Chronic kidney disease management: comparison between renal transplant recipients and non-transplant patients with chronic kidney disease. Nephron Clin Pract. 2007;107:C7-C13.
11. Sharma A, Filler G. Monitoring kidney function and renal disease in children following transplant. Pediatr Health. 2009;3:155-163.
12. Nowicki M, Zwiech R. Chronic renal failure in non-renal organ transplant recipients. Ann Transplant. 2005;10:54-58.
13. Bloom RD, Reese PP. Chronic kidney disease after nonrenal solid-organ transplantation. J Am Soc Nephrol. 2007;18:3031-3041.
14. Manley HJ. Disease progression and the application of evidence-based treatment guidelines diagnose it early: a case for screening and appropriate management. J Manag Care Pharm. 2007;13:S6-S12.
15. Fellström B. Risk factors for and management of post-transplantation cardiovascular disease. Bio Drugs. 2001;15:261-278.
16. Krämer BK, Zülke C, Kammerl MC, et al; European Tacrolimus vs Cyclosporine Microemulsion Renal Transplantation Study Group. Cardiovascular risk factors and estimated risk for CAD in a randomized trial comparing calcineurin inhibitors in renal transplantation. Am J Transplant. 2003;3:982-987.
17. Krämer BK, Böger C, Krüger B, et al. Cardiovascular risk estimates and risk factors in renal transplant recipients. Transplant Proc. 2005;37: 1868-1870.
18. Filler G, Webb NJ, Milford DV, et al. Four-year data after pediatric renal transplantation: a randomized trial of tacrolimus vs cyclosporin micro-emulsion. Pediatr Transplant. 2005;9:498-503.
19. Morales J, Domingez-Gill B. Cardiovascular risk profile with the new immunosuppressive combinations after renal transplantation. J Hypertens. 2005;23:1609-1616. (Pubitemid 41233417)
20. Van Hooff, JP, Gelens M, Boots JM, et al. Preservation of renal function and cardiovascular risk factors. Transplant Proc. 2006;38:1987-1991.
21. Taylor A, Watson C, Bradley J. Immunosuppressive agents in solid organ transplantation: Mechanisms of action and therapeutic efficacy. Crit Rev Oncol/Hematol. 2005;56:23-46.
22. Grenda R. Effects of steroid avoidance and novel protocols on growth in paediatric renal transplant patients. Pediatr Nephrol. 2010;25:747-752.
23. Sarwal MM, Vidhun JR, Alexander SR, et al. Continued superior outcomes with modification and lengthened follow-up of a steroid-avoidance pilot with extended daclizumab induction in pediatric renal transplantation. Transplantation. 2003;76:1331-1339.
24. Li L, Chang A, Naesens M, et al. Steroid-free immunosuppression since 1999: 129 pediatric renal transplants with sustained graft and patient benefits. Am J Transplant. 2009;9:1362-1372.